Factors Associated With Response to Growth Hormone in Pediatric Growth Disorders: Results of a 5-year Registry Analysis
Open Access
- 16 February 2023
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 7 (5), bvad026
- https://doi.org/10.1210/jendso/bvad026
Abstract
Context Growth hormone (GH) therapy can increase linear growth in patients with growth hormone deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS), and Prader-Willi syndrome (PWS), although outcomes vary by disease state. Objective To assess growth and identify factors associated with growth response with long-term GH therapy. Design, Setting, and Participants Data from pediatric patients with GHD, TS, NS, and PWS obtained at GH treatment initiation (baseline) and annually for 5 years in the ANSWER Program and NordiNet® IOS were analyzed retrospectively. Height standard deviation score (HSDS) was assessed over time, and multivariate analyses determined variables with significant positive effects on growth outcomes in each patient cohort. Results Data from patients with GHD (n = 12,683), TS (n = 1307), NS (n = 203), and PWS (n = 102) were analyzed. HSDS increased over time during GH treatment in all cohorts. Factors with significant positive effects on ΔHSDS were younger age at GH initiation and lower HSDS at baseline (all cohorts) and higher GH dose (GHD and TS only); sex had no effect in any cohort. The modeling analysis showed that ΔHSDS was greatest in year 1 and attenuated over consecutive years through year 5. Estimated LS mean ΔHSDS values at year 5 by cohort were 1.702 (females) and 1.586 (males) in GHD, 1.033 in TS, 1.153 in NS, and 1.392 in PWS. Conclusions Long-term GH therapy results in large increases in HSDS in patients with GHD, TS, NS, and PWS. Greater gains in HSDS can be obtained with higher GH doses and earlier initiation of treatment.Keywords
Funding Information
- Novo Nordisk, Inc, Plainsboro, NJ
This publication has 44 references indexed in Scilit:
- The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®)Clinical Epidemiology, 2013
- Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registryInternational Journal of Pediatric Endocrinology, 2012
- Identification of factors associated with good response to growth hormone therapy in children with short stature: results from the ANSWER Program®International Journal of Pediatric Endocrinology, 2011
- Nutritional phases in Prader–Willi syndromeAmerican Journal of Medical Genetics Part A, 2011
- Noonan Syndrome: Clinical Features, Diagnosis, and Management GuidelinesPEDIATRICS, 2010
- Long‐term effects of growth hormone therapy on patients with Prader–Willi syndromeActa Paediatrica, 2010
- Growth hormone treatment and adverse events in Prader–Willi syndrome: data from KIGS (the Pfizer International Growth Database)Clinical Endocrinology, 2006
- Turner Syndrome, Insulin Sensitivity and Growth Hormone TreatmentHormone Research in Paediatrics, 2005
- The Potential of Prediction Models Based on Data from KIGS as Tools to Measure Responsiveness to Growth HormoneHormone Research in Paediatrics, 2001
- Long-Term Therapy with RecombinantEndocrine, 2001